Gao, Yinjie
Stein, Michelle M.
Kase, Matthew
Cummings, Amy L.
Bharanikumar, Ramit
Lau, Denise
Garon, Edward B.
Patel, Sandip P.
Article History
Received: 30 March 2022
Accepted: 3 July 2022
First Online: 26 July 2022
Declarations
:
: Y.G., M.M.S., M.K., D.L., and R.B. are all employees of Tempus Labs. S.P. reports grants and personal fees from AstraZeneca, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Eli Lilly, personal fees from Illumina, personal fees from Rakuten, grants and personal fees from Tempus, grants from Merck, grants from Pfizer, grants from Roche/Genentech, grants from Fate, grants from Genocea, from Iovance, grants from Novartis, outside the submitted work. A.L.C. reports institutional payments from Amgen, a consulting role for Tempus Labs, and serving as an unpaid data chair for the University of California Lung Cancer Consortium Steering Committee. E.B.G. reports a consulting or advisory role for Merck, Bristol-Meyers Squibb, Shionogi, GlaxoSmithKline, Regeneron/Sanofi, Gilead Sciences, Novartis, Personalis, Boehringer Ingelheim, ABL Bio, Xilio, Natera, Eli Lilly, and Eisai. E.B.G also reports research funding from AstraZeneca, Bristol-Myers Squibb, Genentech, Neon Therapeutics, Dynavax, Iovance Biotherapeutics, ABL Bio, Novartis, Lilly, EMD Serono, Merck, and Mirati Therapeutics, outside the submitted work.
: All analyses were performed using de-identified data and, as such, no patient personal information is presented in the study.
: All analyses were performed using de-identified data; IRB exemption Pro00042950 was obtained from Advarra on April 15, 2020.